Clinic
NPI deactivated
Fenix Health, LLC
Fenix Health, LLC was paid $3.81M by Medicaid between Jan 2019 and Jun 2023, across 16 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 42% of everything it billed.
33Billing provider infoFENIX HEALTH, LLC
COLORADO SPRINGS, CO 80918
COLORADO SPRINGS, CO 80918
33aNPI1811467517assigned 11/26/2018
33bProvider typePain Clinic/Center
28Total paid$3.81M
24GClaims60,927
24DCodes billed16
24AFirst – last monthJan 2019 – Jun 2023
Compared with peers
Next to other Pain Clinic/Center providers in Colorado
Rank by total paid#2 of 5
Median peer was paid$931K
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 5,720 | $259K | |
| 2020 | 10,113 | $454K | |
| 2021 | 15,755 | $848K | |
| 2022 | 20,634 | $1.56M | |
| 2023 | 8,705 | $690K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 42% | 20,089 | 18,710 | $1.59M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 21% | 4,102 | 3,553 | $783K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 10% | 2,432 | 2,308 | $384K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.3% | 4,736 | 3,019 | $279K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 6.6% | 2,017 | 1,929 | $250K |
| 80305 | 6.0% | 21,863 | 19,157 | $230K | |
| 20553 | 4.5% | 3,896 | 2,260 | $172K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 571 | 562 | $73K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 859 | 573 | $30K |
| 76942 | <1% | 69 | 40 | $5K | |
| 20552 | <1% | 77 | 57 | $3K | |
| 20561 | <1% | 66 | 45 | $2K |
4 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 20 | $2K |
| 20610 | <1% | 19 | $890.69 | |
| 97032 | <1% | 91 | $625.09 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 20 | $0.30 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPENCER, MICHAEL (CHIEF OPERATING OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Koala Eye Centre PC | Greensboro, NC | $3.17M |
| Infocus Eyewear | Greensboro, NC | $337K |
| Colon & Rectal Surgery Associates LTD | Minneapolis, MN | $53K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.